Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings

There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).